Skip to content
You are now leaving to visit

Ionis and AstraZeneca Advance New Drug for NASH

Ionis earns $30 million license fee for IONIS-AZ6-2.5-L Rx Third drug to enter development under strategic cardiovascular-renal-metabolic collaboration with AstraZeneca CARLSBAD, Calif. , April 9, 2018 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics,